Clovis Oncology Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Out of Business

  • Employees
  • 368

Employees

  • Latest Deal Type
  • Liquidation

Clovis Oncology General Information

Description

Operator of a biotechnology company intended to serve the United States, Europe and other international markets. The company specializes in acquiring, developing and commercializing cancer treatments and diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use, thereby delivering the right drug to the right patient at the right time.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder, CO 80301
  • United States
+1 (303)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder, CO 80301
  • United States
+1 (303)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Clovis Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 11-Jul-2023 Completed Bankruptcy: Liquidation
9. Merger/Acquisition 14-Jun-2022 Cancelled Generating Revenue
8. Secondary Transaction - Open Market Completed Generating Revenue
7. PIPE 26-Nov-2013 Completed Startup
6. IPO 16-Nov-2011 Completed Generating Revenue
5. Debt - General 01-Jun-2011 Completed Startup
4. Early Stage VC (Series B) 18-Nov-2009 Completed Startup
3. Early Stage VC (Series A2) 09-Nov-2009 Completed Startup
2. Early Stage VC (Series A) 25-Jun-2009 $146M $156M Completed Startup
1. Early Stage VC (Series A1) 15-May-2009 $10.1M $10.1M Completed Startup
To view Clovis Oncology’s complete valuation and funding history, request access »

Clovis Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-2
Series A-1 5,044,828 $0.001000 $0.16 $2 $2 1x $2 11.82%
To view Clovis Oncology’s complete cap table history, request access »

Clovis Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to serve the United States, Europe and other international markets. The com
Biotechnology
Boulder, CO
368 As of 2022

Lexington, MA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Clovis Oncology Competitors (84)

One of Clovis Oncology’s 84 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agenus Formerly VC-backed Lexington, MA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Fate Therapeutics Formerly VC-backed San Diego, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
Cardiff Oncology Formerly Angel backed San Diego, CA
You’re viewing 5 of 84 competitors. Get the full list »

Clovis Oncology Patents

Clovis Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021254793-A1 Immunostimulatory agents in combination with angiogenesis inhibitors Inactive 15-Apr-2020
CA-3175356-A1 Immunostimulatory agents in combination with angiogenesis inhibitors Pending 15-Apr-2020
EP-4135752-A1 Immunostimulatory agents in combination with angiogenesis inhibitors Inactive 15-Apr-2020
EP-4135752-A4 Immunostimulatory agents in combination with angiogenesis inhibitors Inactive 15-Apr-2020
US-20210338656-A1 Immunostimulatory agents in combination with angiogenesis inhibitors Inactive 15-Apr-2020 A61K31/47
To view Clovis Oncology’s complete patent history, request access »

Clovis Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Clovis Oncology Acquisitions (1)

Clovis Oncology’s most recent deal was a Merger/Acquisition with E.O.S for . The deal was made on 19-Nov-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
E.O.S 19-Nov-2013 Merger/Acquisition Drug Discovery
To view Clovis Oncology’s complete acquisitions history, request access »

Clovis Oncology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Clovis Oncology’s complete esg history, request access »

Clovis Oncology FAQs

  • When was Clovis Oncology founded?

    Clovis Oncology was founded in 2009.

  • Where is Clovis Oncology headquartered?

    Clovis Oncology is headquartered in Boulder, CO.

  • What is the size of Clovis Oncology?

    Clovis Oncology has 368 total employees.

  • What industry is Clovis Oncology in?

    Clovis Oncology’s primary industry is Biotechnology.

  • Is Clovis Oncology a private or public company?

    Clovis Oncology is a Private company.

  • What is Clovis Oncology’s current revenue?

    The current revenue for Clovis Oncology is .

  • How much funding has Clovis Oncology raised over time?

    Clovis Oncology has raised $558M.

  • Who are Clovis Oncology’s competitors?

    Agenus, Immunocore Holdings, Fate Therapeutics, Ayala Pharmaceuticals, and Cardiff Oncology are some of the 84 competitors of Clovis Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process